Brind.
  1. Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
  2. Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.

Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.

3 reports, 1 independent Updated Sep 17
Gone quiet Reached 3 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.

Who's involved

What this event is mainly about
ModernaMerck KGaA

Keep exploring

Part of

Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker. All 1 developments

Within Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story